查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830916

2025年全球創傷性腦損傷生物標記市場報告

Traumatic Brain Injury Biomarkers Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，創傷性腦損傷生物標記市場發展迅速，預計將從2024年的11.3億美元成長到2025年的13.8億美元，複合年成長率達22.1%。預測期內的成長主要歸因於道路交通事故發生率上升、人們對腦部健康的認知提高、急診就診量增加、軍事相關創傷性腦損傷病例數量增加以及診斷方法的不斷擴展。

預計未來幾年，創傷性腦損傷生物標記市場將呈指數級成長，到2029年市場規模將達到30.3億美元，複合年成長率（CAGR）為21.7%。預測期內的成長主要歸因於對快速診斷工具需求的不斷成長、神經學研究投入的增加、個人化醫療的日益普及、腦損傷生物標記臨床試驗的擴展以及醫療保健支出的增加。預測期內的關鍵趨勢包括蛋白質體學平台的進步、基於血液的生物標記檢測技術的創新、攜帶式診斷設備的開發、神經發炎標記物的研究以及人工智慧在生物標記分析中的應用。

創傷性腦損傷（TBI）生物標記是存在於血液、腦脊髓液和腦組織中的可測量的生物學指標，包括蛋白質、酵素和遺傳物質，它們能夠指示腦損傷的發生和嚴重程度。這些生物標記用於檢測、診斷和監測TBI，從而深入了解損傷程度並指導治療決策。

創傷性腦損傷（TBI）生物標記主要分為蛋白質生物標記、遺傳生物標記和代謝組生物標記三大類。蛋白質生物標記是指腦組織損傷後釋放到血液或腦脊髓液中的特定蛋白質，其檢測可用於評估損傷的存在、嚴重程度和進展。生物標記可從血液、腦脊髓液、尿液和其他樣本中提取，用於診斷、預後和治療監測。主要最終用戶包括醫院、診所、診斷實驗室和研究機構。

2025年，美國關稅的突然上調及其引發的貿易摩擦對製藥公司造成了嚴重衝擊。利潤豐厚的學名藥生產商尤其脆弱，一些公司不得不縮減低利潤藥物的生產規模。生物技術公司也因關稅導致的專用試劑短缺而面臨臨床試驗延期。為因應這一局面，製藥業正在印度和歐洲擴大原料藥的生產，增加庫存，並遊說政府對基本藥物給予貿易豁免。

本研究報告是商業研究公司（The Business Research Company）最新系列報告的一部分，提供創傷性腦損傷生物標記市場統計數據，包括全球市場規模、區域佔有率、競爭對手及其市場佔有率、詳細的市場細分、市場趨勢以及商業機會，為創傷性腦損傷生物標記行業提供成功所需的關鍵數據。本市場研究報告對行業現狀和未來發展趨勢進行了深入分析，為您提供全面的觀點。

預計未來幾年，道路交通事故數量的增加將推動創傷性腦損傷生物標記市場的成長。道路交通事故是造成人身傷害和財產損失的突發事件，通常需要即時醫療干預。此類事故的增加主要是由於都市化和機動化進程導致私家車使用量增加。創傷性腦損傷生物標記能夠快速且準確地評估頭部損傷，從而為這類情況下的救治提供支持。透過檢測血液中的特定蛋白質，這些生物標記能夠幫助臨床醫生在急救現場及時做出治療決策，改善患者的預後。例如，根據歐盟委員會2024年5月發布的道路安全報告，歐盟道路交通事故死亡總數預計將在2022年達到20,634人，高於2021年的19,917人。因此，道路交通事故數量的增加正在推動創傷性腦損傷生物標記市場的發展。

個人化醫療的日益普及預計也將推動創傷性腦損傷生物標記市場的成長。個人化醫療根據患者的遺傳、環境和生活方式因素量身定做治療方案，以最佳化治療效果和預後。基因組技術的進步使得精準識別基因突變和進行標靶治療成為可能，因此對這種治療方式的需求不斷成長。創傷性腦損傷生物標記透過識別與腦損傷相關的特定生物學指標，為個人化醫療做出貢獻。這些技術有助於根據患者的獨特反應制定個人化治療方案，從而改善復健效果並最佳化臨床決策。例如，美國非營利組織個人化醫療聯盟（PMC）於2024年2月報告稱，2023年美國食品藥物管理局（FDA）核准的新個人化藥物數量從2022年的12種增加到26種。因此，個人化醫療的日益普及正在推動創傷性腦損傷生物標記市場的發展。

創傷性腦損傷生物標記市場的主要企業正在開發創新解決方案，例如基於實驗室的血液檢測，以提高腦震盪診斷的速度和準確性。基於實驗室的血液檢測透過測量血液中的特定生物標記來評估腦損傷的存在和嚴重程度，從而實現更快、更客觀的臨床決策。例如，總部位於美國的醫療保健公司雅培實驗室於2025年6月推出了Alinity i和Architect i1000SR實驗室檢測。這些檢測測量兩種關鍵生物標記：膠質纖維酸性蛋白（GFAP）和泛素羧基末端水解酶（UCH）-L1，以幫助臨床醫生在受傷後12小時內評估疑似腦震盪。這些檢測僅需18分鐘即可得出結果，支持在緊急現場快速進行分診，並減少不必要的CT掃描。這項技術創新為醫生提供了一種可靠的工具來識別潛在的創傷性腦損傷患者，標誌著急診在提供快速、循證護理方面取得了重大進展。

創傷性腦損傷生物標記市場由提供生物標記檢驗研究、臨床試驗支援、神經學數據分析、基於生物標記的篩檢計畫和法規諮詢等服務的營業單位所獲得的收入構成。市場價值包括服務供應商銷售的或包含在其服務產品中的相關產品的價值。創傷性腦損傷生物標記市場還包括生物標記檢測套件、實驗室晶片設備、神經影像相關生物標記、生物感測器整合檢測系統和多重診斷平台的銷售。此市場價值為“出廠價”，即產品製造商或創建者銷售給其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接銷售給最終客戶的產品價值。該市場中的產品價值還包括產品創建者銷售的任何相關服務的價值。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球創傷性腦損傷生物標記：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球創傷性腦損傷生物標記市場：成長率分析
  • 全球創傷性腦損傷生物標記市場表現：規模與成長，2019-2024年
  • 全球創傷性腦損傷生物標記市場預測：規模和成長，2024-2029年，2034年
  • 全球創傷性腦損傷生物標記：潛在市場規模 (TAM)

第6章 市場細分

  • 全球創傷性腦損傷生物標記市場按類型、表現和預測分類，2019-2024年、2024-2029年、2034年
  • 蛋白質生物標記
  • 基因生物標記
  • 代謝組學生物標記
  • 全球創傷性腦損傷生物標記市場按樣本類型、表現和預測分類，2019-2024年、2024-2029年、2034年
  • 血
  • 腦脊髓液（CSF）
  • 尿
  • 全球創傷性腦損傷生物標記市場：按應用、性能和預測分類，2019-2024年、2024-2029年、2034年
  • 診斷
  • 預後
  • 監測治療效果
  • 全球創傷性腦損傷生物標記市場按最終用途、性能和預測分類，2019-2024年、2024-2029年、2034年
  • 醫院和診所
  • 診斷實驗室
  • 研究所
  • 全球創傷性腦損傷生物標記市場：蛋白質生物標記細分、按類型、性能和預測（2019-2024年、2024-2029年、2034年）
  • 膠質纖維酸性蛋白（GFAP）
  • 泛素C端水解酵素L1（UCH-L1）
  • S100鈣結合蛋白質B（S100B）
  • 神經元特異性烯醇化酶（NSE）
  • 全球創傷性腦損傷生物標記市場：基因生物標記細分、類型、表現和預測（2019-2024年、2024-2029年、2034年）
  • 載脂蛋白E (APOE) 基因分型
  • 腦源性神經營養因子（BDNF）多態性
  • 白細胞介素-6 (IL-6) 基因突變
  • 腫瘤壞死因子α（TNF-α）多態性
  • 全球創傷性腦損傷生物標記市場：代謝組學生物標記細分、按類型、性能和預測（2019-2024年、2024-2029年、2034年）
  • 乳酸
  • 肌酸
  • 柯林
  • N-乙醯天門冬胺酸（NAA）

第7章 區域和國家分析

  • 全球創傷性腦損傷生物標記市場：按地區、表現和預測分類，2019-2024年、2024-2029年、2034年
  • 全球創傷性腦損傷生物標記市場：國家、表現與預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 創傷性腦損傷生物標記市場：競爭格局
  • 創傷性腦損傷生物標記市場：公司概況
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • BioMerieux SA
  • DiaSorin SpA
  • Abcam Limited
  • Fujirebio Inc.
  • Meso Scale Diagnostics（MSD）
  • Olink Holding AB
  • Quanterix Corporation
  • OriGene Technologies Inc.
  • BioDirection Inc.
  • NanoDx Inc.
  • BrainScope Company Inc.
  • BrainBox Solutions Inc.
  • DiaGenic ASA
  • NeuroTrauma Sciences LLC
  • Banyan Biomarkers Inc.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年創傷性腦損傷生物標記市場：提供新機會的國家
  • 2029年創傷性腦損傷生物標記市場：充滿新機會的細分市場
  • 2029年創傷性腦損傷生物標記市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r37909

Traumatic brain injury (TBI) biomarkers are measurable biological indicators, including proteins, enzymes, or genetic material, present in blood, cerebrospinal fluid, or brain tissue that indicate the occurrence and severity of brain injury. These biomarkers are used to detect, diagnose, and monitor TBI, providing insights into injury extent and informing treatment decisions.

The primary categories of TBI biomarkers include protein biomarkers, genetic biomarkers, and metabolomic biomarkers. Protein biomarkers are specific proteins released into blood or cerebrospinal fluid due to brain tissue damage and can be measured to evaluate the presence, severity, and progression of the injury. Biomarkers can be collected from samples such as blood, cerebrospinal fluid (CSF), and urine, and are applied in diagnosis, prognosis, and monitoring treatment response. Key end users include hospitals and clinics, diagnostic laboratories, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The traumatic brain injury biomarkers market research report is one of a series of new reports from The Business Research Company that provides traumatic brain injury biomarkers market statistics, including the traumatic brain injury biomarkers industry global market size, regional shares, competitors with the traumatic brain injury biomarkers market share, detailed traumatic brain injury biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the traumatic brain injury biomarkers industry. This traumatic brain injury biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The traumatic brain injury biomarkers market size has grown exponentially in recent years. It will grow from $1.13 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to the rising incidence of road traffic accidents, increasing awareness of brain health, growth in emergency room visits, an increase in military-related traumatic brain injury cases, and the expansion of diagnostic options.

The traumatic brain injury biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.03 billion in 2029 at a compound annual growth rate (CAGR) of 21.7%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic tools, growing investments in neurological research, rising adoption of personalized medicine, expansion of clinical trials for brain injury biomarkers, and higher healthcare expenditure. Major trends in the forecast period include advancements in proteomic platforms, innovations in blood-based biomarker detection, development of portable diagnostic devices, research in neuroinflammation markers, and the integration of artificial intelligence in biomarker analysis.

The rising number of road traffic accidents is expected to drive growth in the traumatic brain injury biomarkers market in the coming years. Road traffic accidents are unplanned events that cause injury, harm, or damage, often necessitating immediate medical intervention. The increase in such accidents is largely due to higher private vehicle usage associated with urbanization and motorization. Traumatic brain injury biomarkers support care in these situations by enabling rapid and accurate assessment of head injuries. By detecting specific proteins in the blood, these biomarkers allow clinicians to make timely treatment decisions, improving patient outcomes in emergency settings. For example, according to a May 2024 report on road safety by the European Commission, the total number of road fatalities in the EU reached 20,634 in 2022, up from 19,917 in 2021. Therefore, the growing number of road traffic accidents is fueling the market for traumatic brain injury biomarkers.

The increasing adoption of personalized medicine is also expected to support growth in the traumatic brain injury biomarkers market. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize care and outcomes. The demand for this approach is rising due to advancements in genomic technologies, which allow precise identification of genetic variations and enable targeted therapies. Traumatic brain injury biomarkers contribute to personalized medicine by identifying specific biological indicators associated with brain injuries. They help design individualized treatment plans based on a patient's unique response, enhancing recovery outcomes and optimizing clinical decision-making. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Hence, the growing adoption of personalized medicine is driving the market for traumatic brain injury biomarkers.

Key players in the traumatic brain injury biomarkers market are developing innovative solutions, such as lab-based blood tests, to enhance the speed and accuracy of concussion diagnosis. A lab-based blood test measures specific biomarkers in the blood to assess the presence and severity of brain injuries, enabling earlier and more objective clinical decisions. For example, in June 2025, Abbott Laboratories, a US-based healthcare company, launched the Alinity i and Architect i1000SR lab tests. These tests measure two key biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH)-L1 to help clinicians evaluate suspected concussions within 12 hours of injury. The tests deliver results in just 18 minutes, supporting faster triage decisions in emergency settings and reducing the need for unnecessary CT scans. This innovation provides physicians with a reliable tool for identifying patients with potential traumatic brain injuries and represents a major advancement in providing rapid, evidence-based care in emergency departments.

Major players in the traumatic brain injury biomarkers market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Biogen Inc., BioMerieux S.A., DiaSorin S.p.A., Abcam Limited, Fujirebio Inc., Meso Scale Diagnostics (MSD), Olink Holding AB, Quanterix Corporation, OriGene Technologies Inc., BioDirection Inc., NanoDx Inc., BrainScope Company Inc., BrainBox Solutions Inc., DiaGenic ASA, NeuroTrauma Sciences LLC, and Banyan Biomarkers Inc.

North America was the largest region in the traumatic brain injury biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in traumatic brain injury biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the traumatic brain injury biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The traumatic brain injury biomarkers market consists of revenues earned by entities by providing services such as biomarker validation studies, clinical trial support, neurological data analysis, biomarker-based screening programs, and regulatory consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The traumatic brain injury biomarkers market also includes sales of biomarker assay kits, lab-on-a-chip devices, neuroimaging-linked biomarkers, biosensor-integrated test systems, and multiplex diagnostic platforms. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Traumatic Brain Injury Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on traumatic brain injury biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for traumatic brain injury biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The traumatic brain injury biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Protein Biomarkers; Genetic Biomarkers; Metabolomic Biomarkers
  • 2) By Sample Type: Blood-based; Cerebrospinal Fluid (CSF)-Based; Urine-Based
  • 3) By Application: Diagnosis; Prognosis; Monitoring Treatment Response
  • 4) By End Use: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes
  • Subsegments:
  • 1) By Protein Biomarkers: Glial Fibrillary Acidic Protein (GFAP); Ubiquitin C-Terminal Hydrolase L1 (UCH-L1); S100 Calcium Binding Protein B (S100B); Neuron-Specific Enolase (NSE)
  • 2) By Genetic Biomarkers: Apolipoprotein E (APOE) Genotyping; Brain-Derived Neurotrophic Factor (BDNF) Polymorphism; Interleukin-6 (IL-6) Gene Variants; Tumor Necrosis Factor-Alpha (TNF-a) Polymorphism
  • 3) By Metabolomic Biomarkers: Lactate; Creatine; Choline; N-Acetylaspartate (NAA)
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Biogen Inc.; BioMerieux S.A.; DiaSorin S.p.A.; Abcam Limited; Fujirebio Inc.; Meso Scale Diagnostics (MSD); Olink Holding AB; Quanterix Corporation; OriGene Technologies Inc.; BioDirection Inc.; NanoDx Inc.; BrainScope Company Inc.; BrainBox Solutions Inc.; DiaGenic ASA; NeuroTrauma Sciences LLC; Banyan Biomarkers Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Traumatic Brain Injury Biomarkers Market Characteristics

3. Traumatic Brain Injury Biomarkers Market Trends And Strategies

4. Traumatic Brain Injury Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Traumatic Brain Injury Biomarkers Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Traumatic Brain Injury Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Traumatic Brain Injury Biomarkers Market Growth Rate Analysis
  • 5.4. Global Traumatic Brain Injury Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Traumatic Brain Injury Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Traumatic Brain Injury Biomarkers Total Addressable Market (TAM)

6. Traumatic Brain Injury Biomarkers Market Segmentation

  • 6.1. Global Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Protein Biomarkers
  • Genetic Biomarkers
  • Metabolomic Biomarkers
  • 6.2. Global Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Blood-based
  • Cerebrospinal Fluid (CSF)-Based
  • Urine-Based
  • 6.3. Global Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnosis
  • Prognosis
  • Monitoring Treatment Response
  • 6.4. Global Traumatic Brain Injury Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • 6.5. Global Traumatic Brain Injury Biomarkers Market, Sub-Segmentation Of Protein Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Glial Fibrillary Acidic Protein (GFAP)
  • Ubiquitin C-Terminal Hydrolase L1 (UCH-L1)
  • S100 Calcium Binding Protein B (S100B)
  • Neuron-Specific Enolase (NSE)
  • 6.6. Global Traumatic Brain Injury Biomarkers Market, Sub-Segmentation Of Genetic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Apolipoprotein E (APOE) Genotyping
  • Brain-Derived Neurotrophic Factor (BDNF) Polymorphism
  • Interleukin-6 (IL-6) Gene Variants
  • Tumor Necrosis Factor-Alpha (TNF-伪) Polymorphism
  • 6.7. Global Traumatic Brain Injury Biomarkers Market, Sub-Segmentation Of Metabolomic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lactate
  • Creatine
  • Choline
  • N-Acetylaspartate (NAA)

7. Traumatic Brain Injury Biomarkers Market Regional And Country Analysis

  • 7.1. Global Traumatic Brain Injury Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Traumatic Brain Injury Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Traumatic Brain Injury Biomarkers Market

  • 8.1. Asia-Pacific Traumatic Brain Injury Biomarkers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Traumatic Brain Injury Biomarkers Market

  • 9.1. China Traumatic Brain Injury Biomarkers Market Overview
  • 9.2. China Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Traumatic Brain Injury Biomarkers Market

  • 10.1. India Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Traumatic Brain Injury Biomarkers Market

  • 11.1. Japan Traumatic Brain Injury Biomarkers Market Overview
  • 11.2. Japan Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Traumatic Brain Injury Biomarkers Market

  • 12.1. Australia Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Traumatic Brain Injury Biomarkers Market

  • 13.1. Indonesia Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Traumatic Brain Injury Biomarkers Market

  • 14.1. South Korea Traumatic Brain Injury Biomarkers Market Overview
  • 14.2. South Korea Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Traumatic Brain Injury Biomarkers Market

  • 15.1. Western Europe Traumatic Brain Injury Biomarkers Market Overview
  • 15.2. Western Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Traumatic Brain Injury Biomarkers Market

  • 16.1. UK Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Traumatic Brain Injury Biomarkers Market

  • 17.1. Germany Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Traumatic Brain Injury Biomarkers Market

  • 18.1. France Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Traumatic Brain Injury Biomarkers Market

  • 19.1. Italy Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Traumatic Brain Injury Biomarkers Market

  • 20.1. Spain Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Traumatic Brain Injury Biomarkers Market

  • 21.1. Eastern Europe Traumatic Brain Injury Biomarkers Market Overview
  • 21.2. Eastern Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Traumatic Brain Injury Biomarkers Market

  • 22.1. Russia Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Traumatic Brain Injury Biomarkers Market

  • 23.1. North America Traumatic Brain Injury Biomarkers Market Overview
  • 23.2. North America Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Traumatic Brain Injury Biomarkers Market

  • 24.1. USA Traumatic Brain Injury Biomarkers Market Overview
  • 24.2. USA Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Traumatic Brain Injury Biomarkers Market

  • 25.1. Canada Traumatic Brain Injury Biomarkers Market Overview
  • 25.2. Canada Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Traumatic Brain Injury Biomarkers Market

  • 26.1. South America Traumatic Brain Injury Biomarkers Market Overview
  • 26.2. South America Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Traumatic Brain Injury Biomarkers Market

  • 27.1. Brazil Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Traumatic Brain Injury Biomarkers Market

  • 28.1. Middle East Traumatic Brain Injury Biomarkers Market Overview
  • 28.2. Middle East Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Traumatic Brain Injury Biomarkers Market

  • 29.1. Africa Traumatic Brain Injury Biomarkers Market Overview
  • 29.2. Africa Traumatic Brain Injury Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Traumatic Brain Injury Biomarkers Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Traumatic Brain Injury Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Traumatic Brain Injury Biomarkers Market Competitive Landscape And Company Profiles

  • 30.1. Traumatic Brain Injury Biomarkers Market Competitive Landscape
  • 30.2. Traumatic Brain Injury Biomarkers Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Traumatic Brain Injury Biomarkers Market Other Major And Innovative Companies

  • 31.1. BioMerieux S.A.
  • 31.2. DiaSorin S.p.A.
  • 31.3. Abcam Limited
  • 31.4. Fujirebio Inc.
  • 31.5. Meso Scale Diagnostics (MSD)
  • 31.6. Olink Holding AB
  • 31.7. Quanterix Corporation
  • 31.8. OriGene Technologies Inc.
  • 31.9. BioDirection Inc.
  • 31.10. NanoDx Inc.
  • 31.11. BrainScope Company Inc.
  • 31.12. BrainBox Solutions Inc.
  • 31.13. DiaGenic ASA
  • 31.14. NeuroTrauma Sciences LLC
  • 31.15. Banyan Biomarkers Inc.

32. Global Traumatic Brain Injury Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Traumatic Brain Injury Biomarkers Market

34. Recent Developments In The Traumatic Brain Injury Biomarkers Market

35. Traumatic Brain Injury Biomarkers Market High Potential Countries, Segments and Strategies

  • 35.1 Traumatic Brain Injury Biomarkers Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Traumatic Brain Injury Biomarkers Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Traumatic Brain Injury Biomarkers Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer